Trial Profile
Phase I clinical study of a WT1-W10 peptide immunotherapy combined with standard treatment against diffuse midline glioma (WT1-TR-DMG).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs WT1-W10 peptide vaccine (Primary) ; Bevacizumab; Temozolomide
- Indications Glioblastoma; Glioma
- Focus Adverse reactions
- Acronyms WT1-TR-DMG
- 01 Jul 2019 Status changed from recruiting to completed.
- 07 Jan 2017 New trial record